Table 8.1.
Medical Uses of hydroxyquinine.
Diseases | Indication | References |
---|---|---|
SARS-CoV-2/COVID-19 | 400 mg dose of HCQ sulfate twice a day and 200 mg twice daily for 4 days have been found to be suitable for COVID-19 treatment | [34] |
HIV | Inhibits the posttranslational modification process of glycoprotein 120 (gp 120) | [35] |
Diabetes | Used in combination with insulin or glibenclamide for up to 6 months. Type 1 diabetes mellitus and glucose control | [36] |
Lipid metabolism | Reduction in triglycerides | [37,38] |
Q fever | A combination of HCQ and doxycycline has always been proposed and used for primary treatment for chronic Q-fever | [39] |
Whipple's disease | Whipple's disease is treated using a combination of HCQ and doxycycline | [40] |
Fungal infections | HCQ shows in vitro antifungal activity against intracellular fungi such as Histoplasma capsulatum and neoformans | [41] |
Zika virus | Zika virus, a member of the Flaviviridae family that is spread in humans by mosquitoes and ticks. HCQ prevents these mosquitoes and ticks from spreading the infection | [42] |
Sjogren's syndrome | Sjogren's syndrome is widely treated with HCQ | [43] |
Chikungunya virus | Chikungunya virus is an alphavirus that is mainly transmitted by Aedes aegypti and Aedes albopictus mosquitoes. The combination of methotrexate and sulfasalazine with HCQ showed potent effects. | [44] |
Rheumatic disease (lupus erythematosus) | HCQ is used in mainly cutaneous lupus patients | [45] |
Rheumatoid arthritis | The triple-drug therapy including (methotrexate, sulfasalazine, and HCQ) is considered for treatment | [46] |
Porphyria cutanea tarda (PCT) | Repeated phlebotomy or low-dose regimen of HCQ (100–200 mg twice weekly) | [47] |
Chronic ulcerative stomatitis (CUSs) | HCQ is beneficial for the treatment of CUS | [48] |
Polymorphic light eruption (PLE) | HCQ is effective and safe in the treatment of PLE | [49] |
Cancer/neoplastic | Used to treat cancer with significant direct and indirect effects on the body | [50,51] |